United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $1,202,400.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction that occurred on Wednesday, July 24th. The shares were sold at an average price of $334.00, for a total transaction of $1,202,400.00. Following the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $43,420. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

United Therapeutics Price Performance

Shares of UTHR opened at $338.22 on Friday. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $343.98. The business’s fifty day moving average is $303.01 and its 200 day moving average is $257.47. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. The stock has a market cap of $15.00 billion, a P/E ratio of 15.99, a P/E/G ratio of 1.47 and a beta of 0.55.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The company had revenue of $677.70 million for the quarter, compared to analysts’ expectations of $620.31 million. During the same period last year, the business earned $4.86 EPS. United Therapeutics’s quarterly revenue was up 33.7% compared to the same quarter last year. Sell-side analysts anticipate that United Therapeutics Co. will post 24.87 earnings per share for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Several large investors have recently bought and sold shares of UTHR. Raymond James & Associates lifted its stake in United Therapeutics by 5.1% during the 4th quarter. Raymond James & Associates now owns 29,474 shares of the biotechnology company’s stock valued at $6,481,000 after acquiring an additional 1,420 shares in the last quarter. Blue Trust Inc. lifted its stake in United Therapeutics by 10.0% during the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 46 shares in the last quarter. First Citizens Bank & Trust Co. bought a new position in United Therapeutics during the 4th quarter valued at $420,000. State of Michigan Retirement System lifted its stake in United Therapeutics by 6.2% during the 4th quarter. State of Michigan Retirement System now owns 11,932 shares of the biotechnology company’s stock valued at $2,624,000 after acquiring an additional 700 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in United Therapeutics by 354.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,437 shares of the biotechnology company’s stock valued at $1,196,000 after acquiring an additional 4,240 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

UTHR has been the subject of several recent analyst reports. HC Wainwright raised their price objective on shares of United Therapeutics from $300.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday. Morgan Stanley downgraded shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price objective for the stock from $310.00 to $321.00 in a research report on Thursday, July 11th. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 15th. The Goldman Sachs Group raised their price objective on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Finally, TD Cowen raised their price objective on shares of United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. Two equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $330.64.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.